CF PharmTech (HKSE:02652) Construction In Progress: HK$62.6 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:02652 CF PharmTech Inc HKSE:02652
15 GF Score
Price HK$17.35
! 5 Warning Signs
View Full Analysis

What is CF PharmTech Construction In Progress?

CF PharmTech HKSE:02652 +0.81% 15 Construction In Progress is HK$62.6 Mil as of Dec. 2025. GuruFocus rates HKSE:02652 with a GF Score™ of 15/100. The stock has 5 warning signs investors should review.

CF PharmTech's quarterly construction in progress increased from Dec. 2023 (HK$128.6 Mil) to Dec. 2024 (HK$193.2 Mil) but then declined from Dec. 2024 (HK$193.2 Mil) to Dec. 2025 (HK$62.6 Mil).

CF PharmTech's annual construction in progress increased from Dec. 2023 (HK$128.6 Mil) to Dec. 2024 (HK$193.2 Mil) but then declined from Dec. 2024 (HK$193.2 Mil) to Dec. 2025 (HK$62.6 Mil).

CF PharmTech Construction In Progress Historical Data

* Premium members only.

The historical data trend for CF PharmTech's Construction In Progress can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CF PharmTech Construction In Progress Chart

CF PharmTech Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Construction In Progress
79.61 128.64 193.18 62.63

CF PharmTech Semi-Annual Data
Dec22 Dec23 Dec24 Dec25
Construction In Progress 79.61 128.64 193.18 62.63
HKSE:02652
15GF Score
CF PharmTech Inc HKSE:02652
Construction In Progress is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

CF PharmTech Construction In Progress Calculation

It records the cost of construction work, which is not yet completed (typically, applied to capital budget items). A construction in progress item is not depreciated until the asset is placed in service. Normally, upon completion, a construction in progress item is reclassified, and the reclassified asset is capitalized and depreciated.

What does a Construction In Progress of HK$62.6 Mil mean?
CF PharmTech (HKSE:02652) has a Construction In Progress of HK$62.6 Mil as of Dec. 2025. Construction in Progress records the amount of construction work that is not complete. View historical data on CF PharmTech and its competitors.
Is CF PharmTech's Construction In Progress too high?
CF PharmTech's current Construction In Progress is HK$62.6 Mil. Overall, CF PharmTech has a GF Score™ of 15/100, reflecting its overall financial health beyond just this single metric.
How does CF PharmTech's Construction In Progress compare to ZTS?
CF PharmTech's Construction In Progress of HK$62.6 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Construction In Progress for a Drug Manufacturers company?
A good Construction In Progress depends on the Drug Manufacturers industry context. However, Construction In Progress should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Construction In Progress mean?
A high Construction In Progress can signal that a stock is expensive relative to its fundamentals. Construction in Progress records the amount of construction work that is not complete. View historical data on CF PharmTech and its competitors. CF PharmTech's current Construction In Progress is HK$62.6 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CF PharmTech stock overvalued right now?
CF PharmTech (HKSE:02652) has a current Construction In Progress of HK$62.6 Mil. The current Construction In Progress is HK$62.6 Mil. CF PharmTech's overall GF Score™ is 15/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Construction In Progress calculated?
Construction In Progress is calculated from a company's financial statements. For CF PharmTech (HKSE:02652), the current Construction In Progress is HK$62.6 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

CF PharmTech Business Description

Address No. 16, Hucundang Road, Xiangcheng Economic Development District, Jiangsu, Suzhou, CHN
CF PharmTech Inc is engaged in inhalation drug delivery technology. It is dedicated to building multidisciplinary bridges between complex formulations and unmet clinical needs. The Company is a specialist in the development of complex inhalation formulations with high barriers to entry, and a platform-based pharmaceutical company with integrated capabilities spanning device engineering, precision drug delivery, international regulatory filing, and commercialization. Leveraging its self-developed, globally integrated end-to-end capabilities, from exhalation-powered nasal spray delivery systems and liposomal inhalation technology to small interfering RNA (siRNA) nucleic acid delivery platforms. Its therapeutic areas encompass respiratory diseases and nasal diseases.
15GF Score

Get the complete analysis for HKSE:02652

Construction In Progress is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$17.35
Price